Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001213900-22-049740
Filing Date
2022-08-19
Accepted
2022-08-19 17:01:22
Documents
5
Effectiveness Date
2022-08-19

Document Format Files

Seq Description Document Type Size
1 REGISTRATION STATEMENT ea156670-s8_actiniumpharma.htm S-8 96029
2 OPINION OF HAYNES AND BOONE, LLP. ea156670ex5-1_actiniumpha.htm EX-5.1 9044
3 CONSENT OF MARCUM LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM. ea156670ex23-1_actiniumpha.htm EX-23.1 2015
4 THIRD AMENDMENT TO THE ACTINIUM PHARMACEUTICALS, INC. 2019 STOCK PLAN ea156670ex99-4_actiniumpha.htm EX-99.4 31757
5 FILING FEE TABLE ea156670ex-fee_actiniumpha.htm EX-FILING FEES 51282
  Complete submission text file 0001213900-22-049740.txt   191217
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-266996 | Film No.: 221181489
SIC: 2834 Pharmaceutical Preparations